EXECUTIVE ENGAGEMENTS
POOL
844
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
169
Interactions with Platform & by Email
PARTICIPANTS
34
Unique # Participated
VALIDATIONS
9
Responses Validated*
COMPANIES
42
Responses Validated*
* Login for a full stack data experience
DATE
JAN 2022
TABLES
22
PAGES
93
EDITION
4
PRICE
USD 5600
CODE
MCP22417
*Engagement stats are ongoing and dynamic
RESEARCH MODULES
EXECUTIVES
HIGHLIGHTS & REPORT INDEX
What's New for 2022?
» Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass Research Platform
» Complimentary updates for one year
Amid the COVID-19 crisis, the global market for Oncology Based In-Vivo CRO estimated at US$1.1 Billion in the year 2020, is projected to reach a revised size of US$1.7 Billion by 2027, growing at a CAGR of 7.4% over the analysis period 2020-2027. Solid Tumors, one of the segments analyzed in the report, is projected to record a 7.4% CAGR and reach US$880.9 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Blood Cancer segment is readjusted to a revised 6.2% CAGR for the next 7-year period.
The Oncology Based In-Vivo CRO market in the U.S. is estimated at US$309.9 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$306.3 Million by the year 2027 trailing a CAGR of 7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.9% and 5.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 6% CAGR.
In the global Other Indications segment, USA, Canada, Japan, China and Europe will drive the 8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$283.5 Million in the year 2020 will reach a projected size of US$487.2 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$201.3 Million by the year 2027.
SELECT PLAYERS
Champion Oncology, Inc.; Charles River Laboratory; Covance; Crown Bioscience; Eurofins Scientific; EVOTEC; ICON Plc; Living Tumor Laboratory; MI Bioresearch, Inc.; Taconic Biosciences; The Jackson Laboratory; Wuxi AppTec; Xentech
SEGMENTS
» Indication (Solid Tumors, Blood Cancer, Other Indications)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Impact of Covid-19 and a Looming Global Recession |
| Oncology Based In-Vivo CRO – Global Key Competitors Percentage Market Share in 2022 (E) |
| Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Oncology Based In-Vivo CRO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Oncology Based In-Vivo CRO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Solid Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Solid Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Solid Tumors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Blood Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Blood Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Blood Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027 |
| World Oncology Based In-Vivo CRO Market Analysis of Annual Sales in US$ Thousand for Years 2012 through 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E) |
| USA Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2012, 2021 & 2027 |
| CANADA |
| Canada Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2012, 2021 & 2027 |
| JAPAN |
| Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E) |
| Japan Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2012, 2021 & 2027 |
| CHINA |
| Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E) |
| China Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2012, 2021 & 2027 |
| EUROPE |
| Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E) |
| Europe Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Oncology Based In-Vivo CRO by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Oncology Based In-Vivo CRO by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2021 & 2027 |
| Europe Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2012, 2021 & 2027 |
| FRANCE |
| Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E) |
| France Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2012, 2021 & 2027 |
| GERMANY |
| Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E) |
| Germany Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2012, 2021 & 2027 |
| ITALY |
| Italy Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2012, 2021 & 2027 |
| UNITED KINGDOM |
| Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E) |
| UK Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2012, 2021 & 2027 |
| REST OF EUROPE |
| Rest of Europe Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2012, 2021 & 2027 |
| ASIA-PACIFIC |
| Oncology Based In-Vivo CRO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E) |
| Asia-Pacific Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2012, 2021 & 2027 |
| REST OF WORLD |
| Rest of World Recent Past, Current & Future Analysis for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Oncology Based In-Vivo CRO by Indication - Solid Tumors, Blood Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Oncology Based In-Vivo CRO by Indication - Percentage Breakdown of Value Sales for Solid Tumors, Blood Cancer and Other Indications for the Years 2012, 2021 & 2027 |
| IV. COMPETITION |
| Total Companies Profiled: 42 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com